Capitanio Umberto, Scattoni Vincenzo, Freschi Massimo, Briganti Alberto, Salonia Andrea, Gallina Andrea, Colombo Renzo, Karakiewicz Pierre I, Rigatti Patrizio, Montorsi Francesco
Department of Urology, University Vita-Salute San Raffaele, Scientific Institute Hospital San Raffaele, Milan, Italy.
Eur Urol. 2008 Jul;54(1):118-25. doi: 10.1016/j.eururo.2008.02.018. Epub 2008 Feb 26.
Controversies exist about the most appropriate management for patients with incidental prostate cancer after surgery for benign prostatic hyperplasia (BPH).
To test the accuracy of preoperative clinical variables in predicting the presence of residual disease and biochemical recurrence in patients with incidental prostate cancer treated with radical retropubic prostatectomy.
DESIGN, SETTING, AND PARTICIPANTS: We analyzed 126 T1a-T1b prostate cancers diagnosed at surgery for BPH between 1995 and 2007.
All patients underwent radical retropubic prostatectomy within 6 mo of surgery for BPH.
Univariate and multivariate logistic regression models addressed the association between the predictors (age, prostate-specific antigen [PSA] before and after surgery for BPH, T1a-T1b stage, prostate volume, and Gleason score at surgery for BPH) and the presence of residual cancer at radical retropubic prostatectomy. Cox proportional hazards regression analyses tested the relationship between the same predictors and the rate of biochemical recurrence after radical retropubic prostatectomy.
Seventy-five (59.5%) patients were stage T1a and 51 (40.5%) were stage T1b. At radical retropubic prostatectomy, 21 (16.7%) patients were pT0 and seven (5.6%) patients had extraprostatic disease (pT3). PSA before and after surgery for BPH and Gleason score at surgery for BPH were the only independent predictors of residual cancer at radical retropubic prostatectomy (all p<0.04). Stage (T1a vs T1b) did not predict residual cancer or the rate of biochemical recurrence. With a mean follow-up of 57 mo, the 5- and 10-yr biochemical recurrence-free survival rates were 92% and 87%, respectively. PSA after surgery for BPH and Gleason score at surgery for BPH were the only significant multivariate predictors of biochemical recurrence (all p<0.04). The main limitation of this study is the requirement of an external validation before implementation of the clinical recommendations.
PSA measured before and after surgery for BPH and Gleason score at surgery for BPH were the only significant predictors of the presence of residual cancer at radical retropubic prostatectomy. PSA measured after surgery for BPH and Gleason score at surgery for BPH were the only independent predictors of biochemical recurrence after radical retropubic prostatectomy.
对于良性前列腺增生(BPH)手术后偶然发现前列腺癌患者的最佳治疗方案存在争议。
检验术前临床变量对耻骨后根治性前列腺切除术治疗的偶然前列腺癌患者残留疾病和生化复发情况预测的准确性。
设计、地点和参与者:我们分析了1995年至2007年间在BPH手术中诊断出的126例T1a - T1b期前列腺癌。
所有患者在BPH手术后6个月内接受耻骨后根治性前列腺切除术。
单因素和多因素逻辑回归模型分析了预测因素(年龄、BPH手术前后的前列腺特异性抗原[PSA]、T1a - T1b分期、前列腺体积以及BPH手术时的Gleason评分)与耻骨后根治性前列腺切除术中残留癌的存在之间的关联。Cox比例风险回归分析测试了相同预测因素与耻骨后根治性前列腺切除术后生化复发率之间的关系。
75例(59.5%)患者为T1a期,51例(40.5%)为T1b期。在耻骨后根治性前列腺切除术中,21例(16.7%)患者为pT0,7例(5.6%)患者有前列腺外疾病(pT3)。BPH手术前后的PSA以及BPH手术时的Gleason评分是耻骨后根治性前列腺切除术中残留癌的唯一独立预测因素(所有p<0.04)。分期(T1a与T1b)不能预测残留癌或生化复发率。平均随访57个月,5年和10年无生化复发生存率分别为92%和87%。BPH手术后的PSA以及BPH手术时的Gleason评分是生化复发的唯一显著多因素预测因素(所有p<0.04)。本研究的主要局限性是在实施临床建议前需要外部验证。
BPH手术前后测量的PSA以及BPH手术时的Gleason评分是耻骨后根治性前列腺切除术中残留癌存在的唯一显著预测因素。BPH手术后测量的PSA以及BPH手术时的Gleason评分是耻骨后根治性前列腺切除术后生化复发的唯一独立预测因素。